Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2008 / Cilt: 22 - Sayı: 2

Comparison of the effects and utilization incidence of hormonal treatment and other antiresorptive agents in postmennopausal patients

Postmenopozal hastalarda hormon tedavisi ve diğer antirezorbtif ajanların kullanım yaygınlığı ve etkilerinin karşılaştırılması

Pages
69–79
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was not detected any effect of hormonal treatment on mammographic findings.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the study is to investigate the utilization incidence of hormonal therapy and other antiresorbtive agents in postmenopausal patients appealed to our clinics.
📊
Key Findings & Data:Material and method: This study is a retrospective analysis of records of patients who were admitted to menopause outpatient clinic during February-December 2005.
💡
Conclusion & Impact:It was not detected any effect of hormonal treatment on mammographic findings.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the study is to investigate the utilization incidence of hormonal therapy and other antiresorbtive agents in postmenopausal patients appealed to our clinics. Bone mineral density and mammographic findings were also evaluated. Material and method: This study is a retrospective analysis of records of patients who were admitted to menopause outpatient clinic during February-December 2005. Demographic features, bone mineral densitometers, mammographies and prescribed medications were evaluated. One-way ANOVA, t-test, bivariate correlation analysis were used for statistical analysis (p<0.05 was accepted as statistically significant). Results: Osteoporosis was detected in 61 (%18.3) of total 334 patients. 17 (%27.8) of these patients were taking only hormonal therapy, 15 (%24.5) of them were taking other antiresorbtive agents, 10 (%16.3) both and 19(%31.1) none of them. 135(%40) of patients were receiving hormone treatment. Osteoporosis was not detected in 108(%80) of these patients. There was not any statistically significant bone mineral density differences (L1-L4 and femoral t-scores) between the groups of hormonal therapy and other antiresorbtive agents (p>0.05). Hormone therapy, does not seem to affect the mammographic findings (p>0.005). Conclusion: In our clinic, osteoporosis was not determined in most of the patients in hormonal treatment group. Hormonal treatment or other antirezorbtive agents were preferred similarly according to clinical findings in osteoporotic group. It was not detected any effect of hormonal treatment on mammographic findings.

Özet

Amaç: Bu çalışmada amaç kliniğimize başvuran menopoz hastalarının hormon tedavisi ve diğer antirezorbtif ajanları kullanım yaygınlığını araştırmaktır. Ayrıca hastaların kemik mineral yoğunlukları ve mamografi bulguları da değerlendirilmiştir. Gereç ve yöntem: Bu çalışma, Şubat-Aralık 2005 tarihleri arasında başvuran menopoz hastalarının dosyaları taranarak yapılan retrospektif bir araştırmadır. Hastaların demografik özellikleri, kemik mineral yoğunluğu ve dansiteleri, aldıkları tedaviler ve mamografileri incelenmiştir. İstatistiksel analizde t-test, tek yön ANOVA ve çift değişken korelasyon analizi kullanılmıştır (p 0,05). Hormon tedavisi alanlar ve almayanlar arasında mamografik bulgular açısından anlamlı fark saptanmadı (p>0,05). Sonuç: Kliniğimizde hormon tedavisi tercih edilen hasta grubunun büyük bir kısmını osteoporozu olmayan hastalar oluşturmaktadır. Osteoporozu olanlarda ise hormon tedavisi veya diğer antirezorbtifler hastanın kliniğine göre benzer oranda tercih edilmektedir. Hormon tedavisi almış olmanın mamografik bulgulara etkisi saptanmamıştır.

🔖

Cite This Article

GÖDE, F., DOĞAN, E., SAATLİ, B., POSACI, C. (2008). Comparison of the effects and utilization incidence of hormonal treatment and other antiresorptive agents in postmennopausal patients. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 22 - Sayı: 2, 69–79. https://ajindex.com/articles/198793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility: 7nd eds, chapter, 2005; 16-18
  2. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen / Progestin Interventions (PEPI) trial. JAMA 1996; 276:1389-1396
  3. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321-333
  4. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834-839
  5. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab 2001; 86: 4717-4726
  6. Rymer J. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos İnt 2001; 12: 478-483
  7. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Anoud C. A controlled trial of raloxifene HCI; impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11;835-842
  8. Shelly W, Draper MW, Krishnan V, Wong M, Jafffe RB. Selective Estrogen Receptor Modulators: An update on Recent Clinical Findings. Obstet Gynecol survey 2008; 63; 163-181
  9. Black DM, Cummings SR, Karpf DM et al. Fracture İntervention Trial Research Group, Randomized trial effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541
  10. Hosking D, Chilvers CED, Christiansen C et al. Early Postmenopausal İntervention Cohort Study Group, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Eng J Med 1998; 338: 485-492
  11. Brown JP, Kendler DL, Mc Clung MR et al. The efficacy and tolerability of risedronate once a week for the The treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-111
  12. Hasling C, Charles P, Jensen FT, Mosekilde L. Calcium metabolism in postmenopausal osteoporosis: the influence of dietary calcium and net absorbed calcium. J Bone Min Res 1990; 5: 939-946
  13. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. New Eng J Med 1992; 326: 357-362. 1